The Retinopathy Of Prematurity drugs in development market research report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinopathy Of Prematurity. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Retinopathy Of Prematurity by 23 companies/universities/institutes. The top development phase for Retinopathy Of Prematurity is preclinical with 19 drugs in that stage. The Retinopathy Of Prematurity pipeline has 26 drugs in development by companies and one by universities/ institutes. Some of the companies in the Retinopathy Of Prematurity pipeline products market are: ANBITION, Akebia Therapeutics and Signablok.
The key targets in the Retinopathy Of Prematurity pipeline products market include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), Triggering Receptor Expressed On Myeloid Cells 1 (Triggering Receptor Expressed On Monocytes 1 or CD354 or TREM1), and Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).
The key mechanisms of action in the Retinopathy Of Prematurity pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with two drugs in Phase III. The Retinopathy Of Prematurity pipeline products include seven routes of administration with the top ROA being Intravitreal and seven key molecule types in the Retinopathy Of Prematurity pipeline products market including Small Molecule, and Synthetic Peptide.
Retinopathy Of Prematurity overview
Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder, which usually develops in both eyes, is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. Risk factors for the development of ROP include prematurity, extremely low birth weight, and multiple births.
For a complete picture of Retinopathy Of Prematurity’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
